rolipram has been researched along with Metabolic Diseases in 1 studies
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with rolipram increased the AMPK phosphorylation and SIRT6 levels in the liver and kidney while reducing NF-κB acetylation." | 1.48 | Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder. ( Liang, Y; Liu, Q; Wang, Z; Zhang, L; Zhang, N, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 2 |
| Liang, Y | 1 |
| Zhang, L | 1 |
| Zhang, N | 1 |
| Liu, Q | 1 |
1 other study available for rolipram and Metabolic Diseases
| Article | Year |
|---|---|
Phosphodiesterase 4 inhibitor activates AMPK-SIRT6 pathway to prevent aging-related adipose deposition induced by metabolic disorder.
Topics: 3T3-L1 Cells; Adipose Tissue; Aging; AMP-Activated Protein Kinases; Animals; Calcium-Calmodulin-Depe | 2018 |